Microsoft word - lrrbc_leukoreduced rbc control_blutbildkontrolle_kontrolle_1.docx
BGT BioGenTechnologies GmbH Material Safety Data Sheet
Cat.-No.: LRRBC 1. Identification of Substance: • GHS Product identifier: Hematology Whole Blood Control • Application of the substance / the preparation: In-vitro laboratory reagent or component • Manufacturer/Supplier: BGT BioGenTechnologie GmbH Von-Langen-Weg 10 48565 Steinfurt Germany Tel.: 02551/4090 Fax: 02551/1298 Web: www.biogentechnologies.de E-Mail: info@biogentechnologies.de • Emergency information: 02551/4090 Use only in the event of a CHEMICAL EMERGENCY involving a SPILL, LEAK, FIRE, EXPLOSION, or ACCIDENT. 2. Hazards Identification: • Classification: n/a. The classification was made according to the latest edition of the Globally Harmonized System of Classification and Labeling of Chemicals (GHS). • Emergency overview: ۛ • Special Hazards: The hazardous properties of this product is considered to be limited. o Contains human sourced and/or potentially infectious components. • Routes of exposure: o Inhalation o Ingestion o Skin 3. Information on Ingredients: Contains Content % Classification
Preservatives and Other Non-Hazardous Ingredients ۛ
4. First Aid Measures: • After inhalation: Supply fresh air; consult doctor in case of complaints. • After skin contact: Immediately wash with water and soap and rinse thoroughly. Generally the product does not irritate the skin. • After eye contact: Rinse opened eye for several minutes under running water. Then consult a doctor. • After swallowing: Rinse mouth with water. Seek medical attention and appropriate follow-up. 5. Fire Fighting Measures: • Suitable extinguishing agents: The product is non-flammable. • Protective equipment: No special measures required. 6. Accidental Release Measures: • Person-related safety precautions: Handle as potentially infectious. • Measures for environmental protection: Keep contaminated washing water and dispose of appropriately. • Measures for containment and cleaning: o Absorb liquid components with liquid-binding material. o Pick up mechanically. o Clean the affected area carefully; suitable cleaners are: Disinfectant o Dispose contaminated material as waste according to item 13. • Additional information: No dangerous substances are released. 7. Handling and Storage: • Precautions for safe handling: No special measures required. No special precautions are necessary if used correctly. • Information about protection against explosions and fires: No special measures required. • Conditions for safe storage: None, according to product specifications. BGT BioGenTechnologies GmbH BGT BioGenTechnologies GmbH Material Safety Data Sheet
8. Exposure Controls and Personal Protection: • Control parameters: None known. • Appropriate engineering controls: Follow the usual biosafety practices for handling potentially infectious materials. The following personal protection is recommended: o Gloves made of latex, nitril rubber, e.g. o Safety glasses o Protective work clothing. 9. Physical and Chemical Properties: • Appearance: Red Liquid • Odor: Little to none. • pH: Neutral • Melting point/freezing point: Undetermined. • Boiling point/Boiling range: Undetermined. • Flash point: No data. • Evaporation rate: Undetermined. • Flammability: No data. • Vapor pressure/density: No data. • Relative Density: Undetermined. • Solubility in/Miscibility with Water: Fully miscible • Auto igniting: Product is not self igniting. • Viscosity: Undetermined. 10. Stability and Reactivity: • Reactivity: This product contains low concentrations of Sodium Azide <0.1% (w/w). Sodium Azide can form explosive compounds with heavy metals which, with repeated contact with lead and copper commonly found in plumbing drains may result in the build up of shock sensitive compounds. • Chemical Stability: Stable under normal ambient and storage and handling temperatures. • Thermal decomposition/conditions to be avoided: No decomposition if used according to specifications. • Incompatible materials to be avoided: Metals and metallic compounds • Hazardous decomposition products: No dangerous decomposition products known. 11. Toxicological Information: • Acute toxicity: No toxic effect known. • Skin irritant effect: No irritant effect known. • Eye irritant effect: No irritant effect known. • Sensitization: No sensitizing effects known. • Mutagenicity: No effect known. • Carcinogenicity: No effect known. • Reproductive toxicity: No toxic effect known. • Additional toxicological information: The product is not subject to classification according to the latest edition of the Globally Harmonized System of Classification and Labeling of Chemicals (GHS): When used and handled according to specifications, the product does not have any harmful effects according to our experience and the information provided to us. 12. Ecological Information: • Ecotoxicity: Undetermined. • Biodegradability: Undetermined. • Mobility: Undetermined. 13. Disposal Considerations: • Disposal methods: Dispose of waste in accordance to applicable national, regional, or local regulations. BGT BioGenTechnologies GmbH BGT BioGenTechnologies GmbH Material Safety Data Sheet
14. Transport Information: • UN Number: None • DOT regulations: · Hazard class: None • Land transport ADR/RID (cross-border): Not regulated. • Maritime transport IMDG: Not regulated. • Marine pollutant: No • Air transport ICAO-TI and IATA-DGR: Not regulated. • Transport/Additional information: Not dangerous according to the above specifications. 15. Regulations: US Federal and State Regulations • CERCLA/SARA 302: Sodium Azide is listed. • CERCLA/SARA 304: Sodium Azide is listed. • SARA 313: Sodium Azide is listed. • TSCA (Toxic Substances Control Act): Sodium Azide is listed. • California Proposition 65:
o Chemicals known to cause cancer: 389-08-2: Nalidixic Acid EU Labeling Classification This product is not classified. Canada This product is exempt from WHMIS requirements. 16. Other Information: This information is based on our present knowledge. However, this shall not constitute a guarantee for any specific product features and shall not establish a legally valid contractual relationship. BGT BioGenTechnologies GmbH
Wissenschaftl. Publikationen der Augenabteilung am Akh Linz (Originalarbeiten) 2011 1. An in-vivo Evaluation of Brilliant Blue G in Macular Surgery . Höing A, Remy M, Dirisamer M, Priglinger S, Schönfeld CL, Kampik A, Haritoglou C. Klin Monbl Augenheilkd. 2011 Apr 8. [Epub ahead of print] IF: 0,470 2. Quantification of Contrast Recognizability During Brilliant Blue G (BB
Umgang mit schizophrenen Patienten auf der Notfallstation Eine Erfahrungsanalyse Usha Vimaladas Fachschule für Intensiv- und Notfallpflege Stadtspital Triemli, Zürich Kurs A 08 Abgabedatum: 30.6.2009 Inhaltsverzeichnis Umgang mit schizophrenen Patienten auf der Notfallstation 1 EINLEITUNG 1.1 Themenwahl Seit ich auf der Interdisziplinären Notfallstation des Stadtspitals T